Accordingly, we propose that assessing IκBζ protein levels in tumor biopsies could serve as a diagnostic strategy to identify patients who would benefit from a combined immunotherapy with HDAC3 or EZH2 inhibitors. This evidence concerns the gene HDAC3 and neoplasm.